David H. Goddard

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 390 citations · Full text

Rheumatoid Disorder, Rheumatology, Spirit-p2 Phase 3 +12

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8

Antiperinuclear factor and keratin antibodies in rheumatoid arthritis.

G.D. Johnson, António Carvalho, E. J. Holborow et al. · Annals of the Rheumatic Diseases · 1981 · 64 citations · Full text

Regulation of synovial cell growth: Coexpression of transforming growth factor β and basic fibroblast growth factor by cultured synovial cells

David H. Goddard, Scott L. Grossman, William V. Williams et al. · Arthritis & Rheumatism · 1992 · 47 citations

Intrinsically stable IgG aggregates

D. McCarthy, David H. Goddard, Bethan Pell et al. · Journal of Immunological Methods · 1981 · 41 citations

Self-assembly, Stable Igg Aggregates, Physics +1